OS for subjects in the CHRYSALIS study (ASP2215-CL-0101) according to molecular response. Kaplan-Meier analysis of survival for subjects treated with FLT3-inhibitory doses of gilteritinib (ASP2215), according to ITD VAF detected by the NGS-MRD assay after treatment.